title: Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis and Stent Dysfunction after Preoperative Biliary Drainage in Patients with Malignant Biliary Stricture.
abstract: Objective To retrospectively evaluate the risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) and stent dysfunction after performing preoperative biliary drainage (BD) in patients with malignant biliary stricture. Methods Between January 2003 and February 2013, 105 consecutive patients who had undergone transpapillary BD before surgery were enrolled in this study. Procedure-related complications, stent dysfunction rates, and their respective risk factors were investigated. PEP was defined according to the consensus guidelines. Results Fifty-five patients had bile duct cancer, 31 had pancreatic cancer, 16 had ampullary cancer, and 3 had gallbladder cancer. Endoscopic biliary stenting (EBS) and nasobiliary drainage (NBD) were performed in 84 patients and 21 patients, respectively. PEP occurred in 10% of the patients, with a significantly higher frequency in those with hilar/upper bile duct stricture (p=0.026) and a normal bilirubin level at admission (p=0.016). Of the 84 patients who underwent initial EBS, stent dysfunction occurred in 13%. The mean number of days from EBS to stent dysfunction was 14±12 days. A multivariate analysis revealed a male gender (p=0.048), a stent diameter ≤8 Fr (p=0.036), and an ERCP procedure time ≥45 minutes (p=0.021) to be risk factors for stent dysfunction. No NBD tube dysfunction was observed. Conclusion Patients with upper/hilar bile duct stricture or a normal bilirubin level are at high risk of developing PEP after preoperative BD. NBD or EBS with a large-bore stent is therefore recommended as preoperative BD.
authors.affiliation: Department of Gastroenterology, Sendai City Medical Center, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Hashimoto
authors.forename: Kei
authors.initials: K
authors.lastname: Ito
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Koshida
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Kanno
authors.forename: Takahisa
authors.initials: T
authors.lastname: Ogawa
authors.forename: Kaori
authors.initials: K
authors.lastname: Masu
authors.forename: Yuji
authors.initials: Y
authors.lastname: Iwashita
authors.forename: Jun
authors.initials: J
authors.lastname: Horaguchi
authors.forename: Go
authors.initials: G
authors.lastname: Kobayashi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Noda
mesh_terms: D000368:Aged; D001649:Bile Duct Diseases / Q000209:etiology / Q000628:therapy*; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D003251:Constriction, Pathologic; D004322:Drainage / Q000009:adverse effects* / Q000379:methods; D005260:Female; D005706:Gallbladder Neoplasms / Q000150:complications; D006801:Humans; D008297:Male; D061646:Operative Time; D010190:Pancreatic Neoplasms / Q000150:complications; D010195:Pancreatitis / Q000209:etiology*; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D015607:Stents / Q000009:adverse effects*; D016896:Treatment Outcome